The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
 
Tim H. Brümmendorf
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Janssen; Merck; Novartis; Pfizer
Research Funding - Novartis; Pfizer
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Trovagene (Inst)
 
Lambert Busque
Research Funding - Pfizer
 
Carlo Gambacorti-Passerini
Honoraria - Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Pfizer
 
Leif Stenke
No Relationships to Disclose
 
Andrea Viqueira
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Eric Leip
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Simon Purcell
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Michael W Deininger
Honoraria - Blueprint Medicines; Humana; Incyte; Novartis; Pfizer
Consulting or Advisory Role - Ascentage Pharma; Blueprint Medicines; Dispersol; Fusion Pharmaceuticals; Humana; Incyte; Incyte; Medscape; Novartis; Pfizer; Sangamo Therapeutics; Takeda
Research Funding - Blueprint Medicines; Incyte; Leukemia and Lymphoma Society; Novartis (Inst); Pfizer (Inst); SPARC; Takeda
Expert Testimony - Bristol-Myers Squibb